Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03138720 · ClinicalTrials.gov registry record · Phase 2
Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
A Phase 2 study of Pancreatic Adenocarcinoma and Unresectable Pancreatic Cancer, sponsored by HonorHealth Research Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT03138720: Active Phase 2 study of Pancreatic Adenocarcinoma and Unresectable Pancreatic Cancer, sponsored by HonorHealth Research Institute.
NCT03138720 is a Phase 2 study of Pancreatic Adenocarcinoma and Unresectable Pancreatic Cancer that is active but no longer recruiting, run by HonorHealth Research Institute. The registered enrollment target is 24 participants, below the 99,465-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03138720, a Phase 2 study of Pancreatic Adenocarcinoma and Unresectable Pancreatic Cancer, is active but no longer recruiting, sponsored by HonorHealth Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if the combination of paclitaxel protein bound, gemcitabine, cisplatin, paricalcitol are effective in individuals with resectable and unresectable pancreatic cancer.
Primary Outcome
Laboratory measurements of CA 19-9, a circulating tumor biomarker, were collected after every treatment cycle (approximately 3 weeks/cycle); CA 19-9 normalization after 3 or more treatment cycles was measured.
Conditions Studied
Interventions
- DRUG Paclitaxel Protein Bound (Abraxane)
Study Locations (1)
Arizona
- HonorHealth Research Institute - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-05-23 |
| Est. Completion | 2025-08-01 |
| Phase | Phase 2 |
What the registry record for NCT03138720 still lists
NCT03138720 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 99,465-participant average among 62 other Pancreatic Adenocarcinoma trials with a reported enrollment target (100% lower).
The record links to 4 conditions, with Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Paclitaxel Protein Bound (Abraxane) is the first listed.
NCT03138720 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT03138720 about?
NCT03138720 is a clinical study titled "Pre-operative Treatment for Patients With Untreated Pancreatic Cancer". The purpose of this study is to determine if the combination of paclitaxel protein bound, gemcitabine, cisplatin, paricalcitol are effective in individuals with resectable and unresectable pancreatic cancer.
What is the current status of trial NCT03138720?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2017-05-23. Estimated completion is 2025-08-01.
What conditions does trial NCT03138720 study?
This clinical trial studies the following conditions: Pancreatic Adenocarcinoma, Unresectable Pancreatic Cancer, Resectable Pancreatic Cancer, Neoadjuvant Pancreatic Cancer.
What interventions are being tested in trial NCT03138720?
The interventions under investigation include: Paclitaxel Protein Bound (Abraxane) (DRUG).
Who is sponsoring clinical trial NCT03138720?
This trial is sponsored by HonorHealth Research Institute, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03138720 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03138720's enrollment target sits among peer trials
24 49th of 62 higher than 13 of 62 other Pancreatic Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
RECRUITING · Phase 2
-
A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)
RECRUITING · Phase 2
-
Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
9-ING-41 in Patients with Advanced Cancers
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI